PDB10 TYPE-2 DIABETES IN GERMANY: PREVALENCE AND MEDICATION USE  by Yurgin, N et al.
A157Abstracts
events. Transition probabilities were based on Framingham risk
formulae. RESULTS: Over 10 years, in Type-2 diabetes patients
with controlled LDL-c and low HDL-c (<1mmol/L), addition of
Niaspan® (2g daily) to statin treatment was projected to reduce
the absolute incidence of MI (3.2%), angina (0.7%) and CHD
death (1.6%) compared to statin monotherapy. Relative risk
reductions were 13.3%, 12.5% and 13.1% respectively. In
patients with elevated LDL-c (>3mmol/L), ezetimibe plus statin
was associated with a reduced absolute incidence for MI (2.3%),
angina (0.5%) and CHD death (1.1%) versus statin alone. Rel-
ative risk reductions were 7.7%, 7.4% and 7.9% respectively.
CONCLUSIONS: Over 10 years, both Niaspan® and ezetimibe
may lead to substantial reductions in the cumulative incidence
of CHD events in Type-2 diabetes patients failing to reach cho-
lesterol targets with statin monotherapy. These ﬁndings highlight
the potential long-term beneﬁts of raising HDL-c in Type-2 dia-
betes patients with controlled LDL-c.
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OBJECTIVES: To evaluate the clinical beneﬁts of raising HDL-
c by adding Niaspan® on coronary heart disease (CHD) end-
points in Type-2 diabetes patients on statin therapy. METHODS:
Two successive models were developed to project long-term clin-
ical beneﬁts of treating patients over different time periods. The
ﬁrst model (Monte Carlo simulation) was used to evaluate the
impact of simvastatin treatment on lipid levels and identify
patients with low HDL-c. Baseline cohort characteristics and
effects of statin treatment were taken from the diabetic sub-
population of the 4S study. In patients with HDL-c <1mmol/L,
treatment with statin plus add-on Niaspan® was compared to
statin monotherapy. Niaspan® treatment effects were taken from
several clinical trials as summarized in the European SPC. The
second model was then used to simulate the development of
CHD events based on the Framingham risk formulae. This
Markov model included ﬁve states: no CHD, history of myocar-
dial infarction (MI), history of MI and angina, and dead. Cycle
length was one year. RESULTS: Addition of Niaspan® (2g daily)
to statin treatment was associated with a lower cumulative inci-
dence of CHD events than statin monotherapy. Absolute risk
reductions of 2.1%, 4.0%, and 8.1% for myocardial infarction,
0.5%, 0.9%, and 1.3% for angina, and 1.0%, 1.9%, and 4.0%
for CHD death were projected at time horizons of 5, 10, and 
35 years respectively. CONCLUSIONS: Due to its positive effect
on HDL-c levels, addition of Niaspan® to statin treatment was
projected to reduce the cumulative incidence of CHD events
compared to statin monotherapy in type-2 diabetes patients 
with persistently low HDL-c. These data indicate that as the
treatment period increases, the clinical beneﬁts associated 
with statin plus Niaspan® may also increase compared to statin
monotherapy.
PDB10
TYPE-2 DIABETES IN GERMANY: PREVALENCE AND
MEDICATION USE
Yurgin N1, Secnik K1, Lage MJ2
1Eli Lilly and Company, Indianapolis, IN, USA; 2HealthMetrics
Outcomes Research, LLC, Groton, CT, USA
OBJECTIVE: Type-2 diabetes is recognized as a growing
problem across the world, with the number of individuals diag-
nosed with this disorder expected to approximately double in the
next 25 years. The objective of this study is to examine the preva-
lence of Type-2 diabetes as well as trends in antidiabetic med-
ication use in Germany. METHODS: Data for this study were
obtained from the German Disease Analyzer—Mediplus data-
base. All patients who were identiﬁed with Type-2 diabetes
between 01/01/2001 and 12/31/2003 and who were at least 20
years of age when ﬁrst identiﬁed as having Type-2 diabetes were
included in the prevalence estimate (N = 45988). While the 2003
prevalence estimate was based on data from a three year window,
patient characteristics and medication use was examined for each
of the three calendar years. These cohorts consisted of patients
identiﬁed with Type-2 diabetes who were at least age 20 during
the year (N = 20766 for 2001; N = 22778 for 2002; and N =
23326 for 2003). RESULTS: The prevalence of Type-2 diabetes
was estimated to be 3.93% in 2003. From 2001 to 2003, there
was a decrease in the percentage of patients with Type-2 diabetes
who were not receiving antidiabetic medication (from 34.28%
to 28.27%; p < 0.0001) as well as a signiﬁcant decrease in the
use of sulfonylureas (from 20.02% to 16.02%; p < 0.0001). In
contrast, there were signiﬁcant increases in monotherapy insulin
use (from 7.95% to 9.90%; p < 0.0001), monotherapy met-
formin use (from 14.04% to 18.71%; p < 0.0001), and oral com-
bination antidiabetic medication use (from 14.34% to 16.99%;
p < 0.0001) over the same time period. CONCLUSIONS: The
prevalence estimate conﬁrms that Type-2 diabetes is a signiﬁcant
health concern in Germany. Furthermore, recent trends demon-
strate that physicians are increasingly likely to prescribe antidi-
abetic therapies for the treatment of this disease.
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